Cigna Investments Inc. New reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 6.9% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 5,718 shares of the life sciences company’s stock after selling 425 shares during the period. Cigna Investments Inc. New’s holdings in Illumina were worth $992,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its stake in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares in the last quarter. Vanguard Group Inc. boosted its stake in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock valued at $1,646,479,000 after buying an additional 285,379 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock valued at $161,787,000 after buying an additional 271,461 shares in the last quarter. Baird Financial Group Inc. boosted its stake in Illumina by 1,110.5% in the first quarter. Baird Financial Group Inc. now owns 279,120 shares of the life sciences company’s stock valued at $47,629,000 after buying an additional 256,061 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in Illumina by 60.7% in the first quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock valued at $65,577,000 after buying an additional 145,231 shares in the last quarter. 93.81% of the stock is currently owned by institutional investors and hedge funds.

Illumina, Inc. (NASDAQ ILMN) opened at 194.65 on Friday. The firm has a market capitalization of $28.42 billion, a PE ratio of 39.05 and a beta of 0.83. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.95. The stock’s 50 day moving average is $179.31 and its 200-day moving average is $173.49.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.86 earnings per share. Equities analysts expect that Illumina, Inc. will post $3.65 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/11/illumina-inc-nasdaqilmn-shares-sold-by-cigna-investments-inc-new.html.

ILMN has been the topic of several research analyst reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $187.00 target price (up from $170.00) on shares of Illumina in a research report on Friday, April 14th. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 target price on the stock in a research report on Monday, April 17th. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Thursday, April 13th. Cantor Fitzgerald raised their target price on shares of Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 26th. Finally, BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company. Illumina has a consensus rating of “Hold” and a consensus price target of $177.01.

In other news, EVP Omead Ostadan sold 1,671 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $195.26, for a total value of $326,279.46. Following the completion of the sale, the executive vice president now directly owns 24,571 shares of the company’s stock, valued at $4,797,733.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $175.53, for a total value of $2,632,950.00. Following the completion of the sale, the director now directly owns 534,176 shares of the company’s stock, valued at $93,763,913.28. The disclosure for this sale can be found here. Insiders have sold 134,010 shares of company stock valued at $23,946,015 in the last ninety days. Company insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.